Booth 1353
Hyogo, Japan
VC Cell Therapy (VCCT) is a developer of clinical-stage regenerative cell therapies for retinal degeneration. Two assets under development are allogeneic retinal pigment epithelial cells derived from HLA-KO iPS cells and allogeneic photoreceptor cells prepared as organoids. The VCCT's products have been clinically verified with application to ~10 patients to date, and its unique drug formulation and automated manufacturing capability ensures therapy safety and efficacy.